Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION A DSMB note on an imbalance that is not yet a signal put disproportionate reporting signal workbook in front of regulatory-affairs lead in a mid-size sponsor after a complete response letter. This Pharma & Life Sciences / FDA Response and Labeling decision is the 505(b)(2) bridge is from disproportionate reporting signal workbook, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION Regulatory-affairs lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; disproportionate reporting signal workbook already has the discriminator after a DSMB note on an imbalance that is not yet a signal. 2. Keep Pause the pathway in force until disproportionate reporting signal workbook is completed after a DSMB note on an imbalance that is not yet a signal for regulatory-affairs lead. 3. Treat disproportionate reporting signal workbook as Escalate safety review because both readings appear after a DSMB note on an imbalance that is not yet a signal. 4. Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the decision the 505(b)(2) bridge is turns on in disproportionate reporting signal workbook.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is. 3. Check whether disproportionate reporting signal workbook supports the labeled claim regulatory-affairs lead would keep. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read disproportionate reporting signal workbook against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move the 505(b)(2) bridge is for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal). The follow-on FDA Response and Labeling action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the 505(b)(2) bridge is, then the evidence in disproportionate reporting signal workbook, then the action for regulatory-affairs lead - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - What changes the 505(b)(2) bridge is if a DSMB note on an imbalance that is not yet a signal is later withdrawn - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others